Tam Metin PDF (4158 KB) - Marmara Medical Journal

Ö. TARÇINParaoksonaz-1 ve koroner kalp hastalığıparaoxonase and coronary heart disease in type 2diabetes. Lancet 1995;346(8979):869-872.doi:10.1016/S0140-6736(95)92709-331. Kaman D, İlhan N, Metin K, Akbulut M, Üstündağ B.A preliminary study of human paraoxonase andPON1 L/M55-PON1 Q/R192 polymorphisms inTurkish patients with coronary artery disease. CellBiochem Funct 2009;27:88-92. doi:10.1002/cbf.153932. Özkök E, Aydın M, Babalık E, Özbek Z, İnce N,Kara İ. Combined impact of matrixmetalloproteinase-3 and paraoxonase 1 55/192gene variants on coronary artery disease in TurkishPatients. Med Sci Monit 2008;14(19):536-542.33. Aynacıoğlu AS, Kepekçi Y. The humanparaoxonase Gln-Arg 192(Q/R) polymorphism inTurkish patients with coronary artery disease. Int JCardiol 2000;12:33-37. doi: 10.1016.S0167-5273(00)00242-434. Wheeler JG, Keavney BD, Watkins H, Collins R,Danesh J. Four paraoxonase gene polymorphism in11212 cases of coronary heart diseases and 12786controls: meta-analysis of 43 studies. Lancet2004;363(9410):689-695. doi: 10.1016/S0140-6736(04)15642-035. Tartan Z, Orhan G, Kaşıkçıoğlu H, Uyarel H, ÜnalS, Özer N, Özay B, Çiloğlu F, Çam N. The role ofparaoxonase (PON) enzyme in the extent andseverity of the coronary artery disease in type-2diabetic patients. Heart Vessels 2007;22(3):158-164. doi: 10.1007/s00380-0060957-636. Ferretti G, Bacchetti T, Busni D, et al. Protectiveeffect of paraoxonase activity in high-densitylipoproteins against erythrocyte membranesperoxidation: a comparison between healthysubjects and type 1 diabetic patients. J ClinEndocrinol Metab 2004;89:2957-2962.37. Karabina SA, Lehner AN, Franke E, Parthasara S,Santanam N. Oxidative inactivation of paraoxonaseimplicationsin diabetes mellitus andatherosclerosis. Biochim Biophys Acta2005;1725(2):213-221. doi:10.1016/j.bbagen.2005.07.00538. Flekac M, Skrha J, Zidkova K, Lacinova Z,Hilgertova J. Paraoxonase 1 gene polymorphismsand enzyme activities in diabetes mellitus. PhysiolRes 2008;57(5):717-26.39. Chen X, Wu Y, Liu L, Su Y, Peng Y, Jiang L, Liu X,Huang D. Relationship between high densitylipoprotein antioxidant activity and carotid intimamedia thickness in patients with essentialhypertension. Clin Exp Hypertens 2010;32:13-20.40. Yıldız A, Gür M, Demirbağ R, Yılmaz R, Akyol S,Aslan M, Erel O. Paraoxonase and arylesteraseactivities in untreated dipper and non-dipperhypertensive patients. Clin Biochem 2008;41(10-11):779-784. doi:10.1016/j.clinbiochem.2008.02.01041. Ohkubo T, Imai Y, Tsuji I, Nagai K, Watanabe N,Minami N, et al. Relation between nocturnal declinein blood pressure and mortality. The OhasamaStudy. Am J Hypertens 1997;10:1201-1207. doi:10.1016/S0895-7061(97)00274-442. Metohi H, Ohkubo T, Kikuya M, Asayama K, ObaraT, Hashimoto J, et al. Prognostic significance forstroke of a morning pressor surge and a nocturnalblood pressure decline:the Ohasama study.Hypertension 2006;47:149-154. doi:10.1161/01.HYP.0000198541.12640.0f43. Connelly PW, Zinman B, Maguire GF,Mamakeesick M, Haris SB, Hegele RA, RetnakarenR, hanley AJ. Association of the novelcardiovascular risk factors paraoxonase 1 andcystatin C in type 2 diabetes. J Lipid res2009;50(6):1216-1222. doi: 10.1194/jlr.P80070-JLR20044. Ribas V, Sanchez-Quesada JL, Anton R, CamachoM, Julve J, Escola-Gil JC, Vila L, Ordonez-Llanos J,Blanco-Vaca F. Human apolipoprotein A-IIenrichement displaces paraoxonase from HDL andimpairs its antioxidant properties. Circ Res2004;95:789-797. doi:10.1161/01.RES0000146031.94850.5f45. Paragh G, Seres I, Harangi M, Balogh Z, Illyes L, etal. The effect of micronised fenofibrate onparaoxonase activity in patients with coronary heartdisease. Diabetes Metab 2003;29:613-618. doi:10.1016/S1262-3636(07)70077-046. Beltowski J, Wòjcicka G, Mydlarczyk M, Jamroz A.The effect of peroxisome proliferator-activatedreceptors (PPAR) alpha agonist, fenofibrate, on lipidperoxidation, total antioxidant capacity, andplasma paraoxonase 1(PON1) activity. J PhysiolPharmacol 2002;53:463-475.47. Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk Gy,Paragh Gy. Gemfibrozil increases paraoxonaseactivity in type 2 diabetic patients. A new hypothesisof the beneficial action of fibrates? Diabetes Metab2001;27:604-610.48. Durrington PN, Mackness MI, Bhatnagar D, JulierK, Prais H, Arrol S, Morgan J, Wood GNI. Effects oftwo different fibric acid derivatives on lipoproteins,cholesterol ester transfer, fibrinogen, plasminogenactivator inhibitor and paraoxonase activity in typeIIb hyperlipoproteinemia. Atherosclerosis1998;138:217-225. doi:10.1161/01.ATV.0000027414.34728.1F49. Senti M, Tomas M, Anglada R, Elosua R, MarrugatJ, Covas MI, et al. Inter-relationship of smoking,paraoxonase activity, and leisure time physicalactivity:a population based study. Eur J Int Med2003;14:178-184. doi: 10.10167S0953-6205(03)00041-450. Mouhamed DH, Ezzaher A, Araoud M, Neffati F,Douki W, Najjar MF. Paraoxonase 1(PON1) activityand lipid parameters in Tunusian smokers. Ann BiolClin 2010;68;143-147. doi: 10.1684/abc.2010.041851. James RW, Leviev I, Righetti A. Smoking isassociated with reduced serum paraoxonaseactivity and concentration in patients with coronaryartery disease. Circulation 2000;101:2252-2257.52. Nishio E, Watanabe Y. Cigarette smoke extractsinhibits plasma paraoxonase activity by modificationof the enzyme’s free thiols. Biochem Biophys ResComm 1997;236:289-293. doi:10.1006/bbrc.1997.696163Marmara Medical Journal 2011; 24 (1):59-63